Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment

Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment

Bo Wu,1,2,* Shu-Ting Lu,1,* Liu-Jie Zhang,2 Ren-Xi Zhuo,2 Hai-Bo Xu,1 Shi-Wen Huang2 1Department of Radiology, Zhongnan Hospital of Wuhan University, 2Key Laboratory of Biomedical Polymers of Ministry of Education, Department of Chemistry, Wuhan University, Wuhan, People’s Republic of Chi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wu B, Lu S, Zhang L, Zhuo RX, Xu HB, Huang SW
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Triptolide
Co-delivery
reduction-sensitive
synergistic effect
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/3ce1ce16bb794907aed876199e590642
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:3ce1ce16bb794907aed876199e590642
record_format dspace
spelling oai:doaj.org-article:3ce1ce16bb794907aed876199e5906422021-12-02T01:46:43ZCodelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment1178-2013https://doaj.org/article/3ce1ce16bb794907aed876199e5906422017-03-01T00:00:00Zhttps://www.dovepress.com/codelivery-of-doxorubicin-and-triptolide-with-reduction-sensitive-lipi-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Bo Wu,1,2,* Shu-Ting Lu,1,* Liu-Jie Zhang,2 Ren-Xi Zhuo,2 Hai-Bo Xu,1 Shi-Wen Huang2 1Department of Radiology, Zhongnan Hospital of Wuhan University, 2Key Laboratory of Biomedical Polymers of Ministry of Education, Department of Chemistry, Wuhan University, Wuhan, People’s Republic of China *These authors contributed equally to this work Abstract: Codelivery is a promising strategy to overcome the limitations of single chemotherapeutic agents in cancer treatment. Despite progress, codelivery of two or more different functional drugs to increase anticancer efficiency still remains a challenge. Here, reduction-sensitive lipid–polymer hybrid nanoparticles (LPNPs) drug delivery system composed of monomethoxy-poly(ethylene glycol)-S-S-hexadecyl (mPEG-S-S-C16), soybean lecithin, and poly(d,l-lactide-co-glycolide) (PLGA) was used for codelivery of doxorubicin (DOX) and a Chinese herb extract triptolide (TPL). Hydrophobic DOX and TPL could be successfully loaded in LPNPs by self-assembly. More importantly, drug release and cellular uptake experiments demonstrated that the two drugs were reduction sensitive, released simultaneously from LPNPs, and taken up effectively by the tumor cells. DOX/TPL-coloaded LPNPs (DOX/TPL-LPNPs) exhibited a high level of synergistic activation with low combination index (CI) in vitro and in vivo. Moreover, the highest synergistic therapeutic effect was achieved at the ratio of 1:0.2 DOX/TPL. Further experiments showed that TPL enhanced the uptake of DOX by human oral cavity squamous cell carcinoma cells (KB cells). Overall, DOX/TPL-coencapsulated reduction-sensitive nanoparticles will be a promising strategy for cancer treatment. Keywords: triptolide, codelivery, reduction sensitive, synergistic effectWu BLu SZhang LZhuo RXXu HBHuang SWDove Medical PressarticleTriptolideCo-deliveryreduction-sensitivesynergistic effectMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 1853-1862 (2017)
institution DOAJ
collection DOAJ
language EN
topic Triptolide
Co-delivery
reduction-sensitive
synergistic effect
Medicine (General)
R5-920
spellingShingle Triptolide
Co-delivery
reduction-sensitive
synergistic effect
Medicine (General)
R5-920
Wu B
Lu S
Zhang L
Zhuo RX
Xu HB
Huang SW
Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment
description Bo Wu,1,2,* Shu-Ting Lu,1,* Liu-Jie Zhang,2 Ren-Xi Zhuo,2 Hai-Bo Xu,1 Shi-Wen Huang2 1Department of Radiology, Zhongnan Hospital of Wuhan University, 2Key Laboratory of Biomedical Polymers of Ministry of Education, Department of Chemistry, Wuhan University, Wuhan, People’s Republic of China *These authors contributed equally to this work Abstract: Codelivery is a promising strategy to overcome the limitations of single chemotherapeutic agents in cancer treatment. Despite progress, codelivery of two or more different functional drugs to increase anticancer efficiency still remains a challenge. Here, reduction-sensitive lipid–polymer hybrid nanoparticles (LPNPs) drug delivery system composed of monomethoxy-poly(ethylene glycol)-S-S-hexadecyl (mPEG-S-S-C16), soybean lecithin, and poly(d,l-lactide-co-glycolide) (PLGA) was used for codelivery of doxorubicin (DOX) and a Chinese herb extract triptolide (TPL). Hydrophobic DOX and TPL could be successfully loaded in LPNPs by self-assembly. More importantly, drug release and cellular uptake experiments demonstrated that the two drugs were reduction sensitive, released simultaneously from LPNPs, and taken up effectively by the tumor cells. DOX/TPL-coloaded LPNPs (DOX/TPL-LPNPs) exhibited a high level of synergistic activation with low combination index (CI) in vitro and in vivo. Moreover, the highest synergistic therapeutic effect was achieved at the ratio of 1:0.2 DOX/TPL. Further experiments showed that TPL enhanced the uptake of DOX by human oral cavity squamous cell carcinoma cells (KB cells). Overall, DOX/TPL-coencapsulated reduction-sensitive nanoparticles will be a promising strategy for cancer treatment. Keywords: triptolide, codelivery, reduction sensitive, synergistic effect
format article
author Wu B
Lu S
Zhang L
Zhuo RX
Xu HB
Huang SW
author_facet Wu B
Lu S
Zhang L
Zhuo RX
Xu HB
Huang SW
author_sort Wu B
title Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment
title_short Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment
title_full Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment
title_fullStr Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment
title_full_unstemmed Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment
title_sort codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/3ce1ce16bb794907aed876199e590642
work_keys_str_mv AT wub codeliveryofdoxorubicinandtriptolidewithreductionsensitivelipidndashpolymerhybridnanoparticlesforinvitroandinvivosynergisticcancertreatment
AT lus codeliveryofdoxorubicinandtriptolidewithreductionsensitivelipidndashpolymerhybridnanoparticlesforinvitroandinvivosynergisticcancertreatment
AT zhangl codeliveryofdoxorubicinandtriptolidewithreductionsensitivelipidndashpolymerhybridnanoparticlesforinvitroandinvivosynergisticcancertreatment
AT zhuorx codeliveryofdoxorubicinandtriptolidewithreductionsensitivelipidndashpolymerhybridnanoparticlesforinvitroandinvivosynergisticcancertreatment
AT xuhb codeliveryofdoxorubicinandtriptolidewithreductionsensitivelipidndashpolymerhybridnanoparticlesforinvitroandinvivosynergisticcancertreatment
AT huangsw codeliveryofdoxorubicinandtriptolidewithreductionsensitivelipidndashpolymerhybridnanoparticlesforinvitroandinvivosynergisticcancertreatment
_version_ 1718402888719400960

Ejemplares similares